HILDEN, Germany, and GERMANTOWN, Maryland, April 12, 2017
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that two peer-reviewed studies indicate the potential additional clinical value for QuantiFERON-TB® Gold Plus (QFT-Plus®), the fourth-generation test using enhanced QuantiFERON technology to detect latent tuberculosis (TB) infection. Both studies focus on potential benefits of novel CD8+ T-cell stimulating antigens contained in QFT-Plus. A study at the Stanford University School of Medicine is the first publication describing the performance of QFT-Plus in healthcare workers, while a study at Japan's National Hospital Organization Hokkaido Medical Center provides the first evidence for QFT-Plus as a potential monitoring aid during treatment of active TB.
"These studies add to a growing body of clinical evidence on QuantiFERON-TB Plus, suggesting added utility for our novel CD8+ T-cell technology. We have introduced QFT-Plus in more than 60 markets since 2015 to aid in tuberculosis control by screening at-risk populations for latent TB infection," said Dr. Masae Kawamura, Senior Director, TB Medical and Scientific Affairs, at QIAGEN. "The unique ability of QFT-Plus to measure CD8+ immune response has led the World Health Organization to suggest that the new test offers potential for identifying patients at greater risk of progressing to active TB. A number of clinical studies are underway to explore broader applications based on the CD8+ capability, although regulatory approvals to date focus on the effectiveness of QFT-Plus in detecting latent TB infection."
Click here for the full press release
SOURCE QIAGEN N.V.
Subscribe to our Free Newsletters!
Opportunistic infections are microbial infections that can cause disease in persons with a weak ...
The state health insurance programs provide health care support to the below poverty line (BPL) ...
There is a lining between the lungs and chest wall known as Pleura. The dismissal of pleura by a ...View All